SCHEMBL21481820

SCHEMBL21481820

O=C(NC1CCC(C(=O)O)CC1)c1ccc(F)c2cc[nH]c12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAF1 P21675 1/20 0.42
▸ CECR2 Q9BXF3 1/20 0.42
▸ BRD9 Q9H8M2 1/20 0.42
▸ HPGD P15428 3/20 0.41
▸ JAK2 O60674 2/20 0.39
▸ NTRK1 P04629 2/20 0.39
▸ CD38 P28907 2/20 0.39
▸ TGFBR1 P36897 2/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ KDM1A O60341 1/20 0.39
▸ MAOA P21397 1/20 0.39
▸ BTK Q06187 1/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ AR P10275 1/20 0.38
▸ SMYD3 Q9H7B4 1/20 0.38
▸ HSD11B1 P28845 1/20 0.37
▸ P2RX7 Q99572 1/20 0.37
▸ SELL P14151 1/20 0.37
▸ SELP P16109 1/20 0.37
▸ SELE P16581 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21506731 1.00 TAF1 (0.42) TAF1CECR2BRD9HPGDJAK2
SCHEMBL22927192 0.86 PTGER4 (0.38) TAF1CECR2BRD9HPGDCD38
SCHEMBL24991888 0.85 P2RX7 (0.46) TAF1CECR2BRD9HPGDJAK2
SCHEMBL21481904 0.85 P2RX7 (0.46) TAF1CECR2BRD9HPGDJAK2
SCHEMBL21506647 0.78 P2RX7 (0.39) TAF1CECR2BRD9BTKP2RX7
SCHEMBL22927154 0.77 JAK1 (0.44) TAF1CECR2BRD9JAK2CD38
SCHEMBL26432933 0.77 TAF1 (0.39) TAF1CECR2BRD9CD38TGFBR1
SCHEMBL22927186 0.76 TAF1 (0.37) TAF1CECR2BRD9CD38BTK
SCHEMBL23185735 0.75 JAK1 (0.42) TAF1CECR2BRD9JAK2CD38
SCHEMBL5187097 0.72 KEAP1 (0.49) BTKP2RX7KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795156-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2023-10-24 — — US disclosed
US-20230045612-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2023-02-09 — — US disclosed
US-10968201-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2021-04-06 — — US disclosed
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2021-01-28 — — US disclosed
WO-2019204523-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. (US) 2019-10-24 — — WO disclosed
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2019-10-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795156-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 TAF1 4299/4885CECR2 390/4885BRD9 655/4885
US-10968201-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 TAF1 4299/4885CECR2 390/4885BRD9 655/4885
US-20230045612-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 TAF1 4299/4885CECR2 390/4885BRD9 655/4885
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 TAF1 4299/4885CECR2 390/4885BRD9 655/4885
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 TAF1 4299/4885CECR2 390/4885BRD9 655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback